Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE

NCT03185481 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03185481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03185481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
July 6, 2017
Completion date
October 25, 2017
Enrollment
5 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease with motor fluctuations